Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 20 · below the Ichimoku cloud · RSI 49 · MACD above its signal
| 6.80 | 52-week high | +84.78% |
| 5.26 | R3 (classic) | +42.93% |
| 5.01 | Previous month high | +36.14% |
| 4.77 | R2 (classic) | +29.62% |
| 4.45 | R1 (classic) | +20.92% |
| 4.40 | Previous week high | +19.57% |
| 4.28 | Previous day high | +16.30% |
| 3.96 | Pivot | +7.61% |
| 3.68 | Price now | |
| 3.64 | S1 (classic) | −1.09% |
| 3.47 | Previous day low | −5.71% |
| 3.20 | Previous week low | −13.04% |
| 3.15 | S2 (classic) | −14.40% |
| 3.09 | Previous month low | −16.03% |
| 2.83 | S3 (classic) | −23.10% |
| 2.79 | 52-week low | −24.18% |
None of the 29 investors followed here reported a position in CCM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CCM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CCM.
TimeframesDown on the weekly and monthly, mixed on the hourly and daily.
pulling back under the 21 EMA
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.2 | -10.3 | 5.5 | 2.9 | 24.8 | -4.3 | -6.1 | 2.9 | -31.1 | 17.2 | −4.7% | ||
| 2025 | -3.3 | -0.2 | -22.9 | 112.8 | -14.2 | -21.5 | -13.1 | 4.8 | 17.6 | -11.1 | -29.1 | -0.3 | −28.3% |
| 2024 | -29.1 | -37.2 | 12.2 | 54.5 | -41.2 | 90.0 | -17.1 | -17.6 | 8.0 | 10.3 | -34.2 | 5.7 | −51.1% |
| 2023 | -18.3 | 6.0 | -12.0 | 6.4 | 2.3 | 1.5 | 2.9 | -2.8 | -7.2 | -12.5 | -9.8 | 8.9 | −32.9% |
| 2022 | -3.0 | 8.8 | -19.0 | -12.9 | 8.7 | 16.0 | 4.8 | -1.0 | -5.1 | -30.8 | 18.0 | 8.6 | −18.0% |
| 2021 | 31.0 | 0.3 | 6.7 | -11.5 | -2.9 | -13.0 | 3.8 | -15.1 | 22.1 | -20.1 | -8.5 | -11.5 | −27.0% |
| 2020 | 3.4 | -16.7 | -21.7 | -5.0 | -18.7 | 18.7 | 7.9 | 15.2 | -3.4 | -6.6 | 2.7 | 44.2 | +2.6% |
| 2019 | -15.4 | 3.0 | -9.7 | -16.4 | 8.5 | -11.8 | 19.6 | -4.9 | -5.5 | 11.2 | -0.4 | 0.0 | −25.0% |
| 2018 | -11.1 | -11.5 | 9.2 | 43.4 | 1.0 | 0.2 | -6.5 | -10.3 | 2.0 | 4.8 | 0.0 | -4.3 | +6.9% |
| 2017 | -0.7 | 6.1 | -2.7 | -7.0 | -15.9 | 1.6 | 6.1 | 1.0 | -12.7 | 5.4 | 5.4 | -14.6 | −27.6% |
| 2016 | -2.5 | -3.0 | 7.4 | -0.6 | -19.6 | -2.0 | 13.0 | -2.5 | -6.1 | 10.8 | 2.5 | 1.8 | −5.0% |
| 2015 | 3.6 | 3.3 | -14.4 | 22.0 | -3.8 | 2.3 | -19.0 | -9.1 | -10.4 | 8.2 | -3.8 | 0.0 | −24.5% |
| 2014 | 14.3 | 61.3 | -14.9 | -8.2 | 3.5 | 12.0 | 3.5 | -2.0 | -11.5 | 2.8 | -6.1 | -7.8 | +33.2% |
| 2013 | 3.9 | -0.9 | 2.4 | -2.5 | -3.1 | -2.2 | 2.5 | 21.4 | 6.4 | -1.3 | 0.4 | 4.0 | +32.7% |
| 2012 | 11.8 | 7.5 | -1.0 | -0.3 | -15.7 | -9.3 | -3.1 | 4.9 | 25.8 | 17.3 | 0.9 | -7.0 | +27.9% |
| 2011 | -2.3 | -13.3 | -9.7 | -3.4 | -20.0 | -3.2 | -11.8 | 1.3 | -16.4 | 14.9 | -5.0 | -6.4 | −56.3% |
| 2010 | 14.7 | -13.6 | -20.4 | 6.6 | -12.0 | -6.7 | -4.0 | 15.6 | 5.9 | 1.0 | 6.9 | -2.2 | −14.5% |
| 2009 | — |
No analyst coverage for this instrument.
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.